Latest Conference Articles

March 27th 2023, 6:26pm

SGO Annual Meeting

The combination of durvalumab, tremelimumab, and hypofractionated radiotherapy demonstrated early tolerability in patients with gynecologic malignancies and elicited objective responses in those with PD-L1–high tumors.

March 27th 2023, 5:55pm

SGO Annual Meeting

Robert L. Coleman, MD, FACOG, FACS, discusses an analysis of the phase 3 SORAYA trial evaluating response rates in patients with platinum-resistant ovarian cancer who received mirvetuximab soravtansine at different points in their disease course.

March 27th 2023, 4:45pm

SGO Annual Meeting

Ursula A. Matulonis, MD, discusses final overall survival results from the phase 3 NOVA trial in patients with ovarian cancer.

March 27th 2023, 4:39pm

SGO Annual Meeting

Women with ovarian cancer may be effectively assessed for frailty status via the Carolina Frailty Index Score.

March 27th 2023, 4:03pm

SGO Annual Meeting

The recommended phase 2 dose of olaparib plus selumetinib generated a clinical benefit in patients with endometrial or ovarian cancer harboring RAS mutations, according to findings from the dose-expansion portion of the phase 1b SOLAR trial.

March 27th 2023, 3:15pm

SGO Annual Meeting

The use of an individualized starting dose and dose modifications due to treatment-emergent adverse effects did not impact the efficacy of maintenance niraparib in patients with newly diagnosed ovarian cancer, irrespective of BRCA mutation status.

March 27th 2023, 1:47pm

SGO Annual Meeting

Neoadjuvant treatment with the combination of durvalumab plus tremelimumab and chemotherapy elicited a promising 12-month progression-free survival rate in patients with advanced-stage ovarian cancer.

March 26th 2023, 9:00pm

SGO Annual Meeting

The gynecological cancer lymphedema questionnaire and the lower extremity lymphedema screening questionnaire showed moderate to substantial agreement across different cutoff points.

March 26th 2023, 3:06pm

SGO Annual Meeting

Administration of hyperthermic intraperitoneal chemotherapy with cytoreductive surgery did not have a negative impact on health-related quality of life compared with cytoreductive surgery alone in patients with newly diagnosed ovarian cancer, according to findings from a phase 2 trial.

March 14th 2023, 5:00pm

PER® New York GU

Although the immune system plays a vital role in attacking tumor cells, the immune mechanisms vary from tumor to tumor, and factors in the tumor microenvironment can reduce the effectiveness of the body’s immune response.

March 13th 2023, 11:45pm

PER® New York GU

Despite a perhaps overwhelming number of combination regimens available for use in the frontline setting for patients with renal cell carcinoma, treatment decisions can still largely boil down to a patient’s risk status. For second-line therapy, investigators are looking to contemporary trials for guidance.

March 11th 2023, 11:00am

PER® New York GU

Patients with metastatic castration-resistant prostate cancer have traditionally been burdened by a poor outlook; however, emerging therapeutic targets and novel agents directed at them are poised to affect change in this population.

March 6th 2023, 2:00pm

PER® Miami Breast Cancer Conference

Hyman B. Muss, MD, discusses the potential benefits of metronomic chemotherapy and which patients with metastatic breast cancer could be candidates, as well as how to approach end-of-life conversations and decisions for patients.

March 5th 2023, 2:18pm

PER® Miami Breast Cancer Conference

Lisa A. Carey MD, ScM, FASCO, discusses the use of response-guided therapy in HER2-positive breast cancer.

March 5th 2023, 2:11pm

PER® Miami Breast Cancer Conference

Patrick I. Borgen, MD, discusses on the importance of addressing the opioid epidemic through the lens of breast cancer care.

March 5th 2023, 11:00am

PER® Miami Breast Cancer Conference

In a single-center study, investigators assessed real-world outcomes in patients with metastatic metastatic triple-negative breast cancer treated with the antibody-drug conjugate sacituzumab govitecan-hziy.

March 4th 2023, 8:52pm

PER® Miami Breast Cancer Conference

Lindsay Avner Kaplan and Nancy G. Brinker, the keynote speakers of the 40th Annual Miami Breast Cancer Conference, discuss the need to confront social determinants of health for patients and drive the public conversation and interpretation of personal and clinical stories in health care.

March 4th 2023, 8:25pm

PER® Miami Breast Cancer Conference

After settling the debate of which patients with early-stage, hormone receptor–positive breast cancer require chemotherapy in addition to endocrine therapy, investigators have set their sights on determining whether ovarian function suppression can deliver the same effects of chemotherapy and when to recommend abemaciclib and olaparib.

March 4th 2023, 5:47pm

PER® Miami Breast Cancer Conference

Novel selective estrogen receptor modulators, selective estrogen receptor degraders, and proteolysis-targeting chimera inhibitors have demonstrated early efficacy for patients with breast cancer who experience disease progression following CDK4/6 inhibitor treatment.

March 4th 2023, 5:26pm

PER® Miami Breast Cancer Conference

Brain metastases are a common complication in patients with breast cancer, and although systemic therapies for patients with HER2-positive disease have displayed promise in penetration of the blood-brain barrier, work remains for subsets of patients with central nervous system metastases.